File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Conference Paper: Sitagliptin Use in a Large Cohort of Chronic Hepatitis B with Concomitant Diabetes was Associated with Increased Risk of Severe Liver Fibrosis
Title | Sitagliptin Use in a Large Cohort of Chronic Hepatitis B with Concomitant Diabetes was Associated with Increased Risk of Severe Liver Fibrosis |
---|---|
Authors | |
Issue Date | 2019 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ |
Citation | The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019, Boston, MA, USA, 8-12 November 2019. In Hepatology, 2019, v. 70 n. Suppl. 1, p. 1127A-1128A, abstract no. 1878 How to Cite? |
Abstract | Background: Diabetes mellitus is associated with adverse
liver-related outcomes including liver decompensation
and hepatocellular carcinoma. Its specific interaction with
chronic hepatitis B (CHB) and related liver fibrosis is not wellunderstood . Methods: We prospectively recruited consecutive
CHB patients with concomitant type 2 diabetes mellitus .
Anthropometry, metabolic parameters, liver biochemistry and
virologic profiles were measured. Detailed diabetic history
(duration, treatment, glycemic control, complications) was
collected. Liver fibrosis and steatosis were assessed by
transient elastography (Fibroscan, Echosens), with severe
fibrosis defined following the European Association of the
Study of the Liver guidelines for CHB (liver stiffness [LS]>9.0
kPa with normal alanine aminotransferase (ALT) level, or
>12.0 kPa with ALT one to five times above the upper limit
of normal) . Results: 755 diabetic CHB patients (mean age
63 .1±9 .6 years, 65 .7% male) were recruited . 488 (64 .6%) were
on nucleoside analogue treatment for a median duration of
6.6 years. The median duration of diabetes was 8.8 (IQR 4.5–
14.7) years. Median LS was 6.8 (IQR 5.2–10.3) kPa, with 218
(28.9%) having severe liver fibrosis. 94 (12.5%) and 57 (7.5%)
were on sitagliptin and other dipeptidyl peptidase-4 inhibitors
(DPP-4is) respectively . By multivariable analysis, after
controlling for CHB treatment status, metabolic comorbidities,
diabetes duration, presence of diabetic complications and
time-weighted glycosylated haemoglobin levels since diabetes
diagnosis, the use of sitagliptin was independently associated
with severe liver fibrosis (OR 2.04, 95%CI 1.19–3.48;
p=0.009). Sitagliptin use for >3 years was similarly associated
(OR 2 .68, 95% CI 1 .11-6 .51; p=0 .029) . Other DPP-4is did
not show such association (p=0 .405) . Additional associated
factors included severe steatosis (controlled attenuation
parameter ≥280 dB/m) (OR 1.97, 95%CI 1.16–3.33; p=0.012)
and the presence of diabetic microvascular complications
(OR 1 .60, 95%CI 1 .07-2 .39; p=0 .024) . Statins treatment was
the only negative predictor of severe liver fibrosis (OR 0.52,
95%CI 0 .35–0 .77; p=0 .001) . Conclusion: Sitagliptin use in
diabetic CHB patients was associated with an increased risk
of severe liver fibrosis. Its potential fibrogenic effect requires longitudinal and mechanistic validation.
[https://doi.org/10.1002/hep.30941] |
Description | Poster Abstract - no. 1878 |
Persistent Identifier | http://hdl.handle.net/10722/280993 |
ISSN | 2023 Impact Factor: 12.9 2023 SCImago Journal Rankings: 5.011 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ma, HJ | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Lee, CHP | - |
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.contributor.author | Seto, WKW | - |
dc.date.accessioned | 2020-02-25T07:43:43Z | - |
dc.date.available | 2020-02-25T07:43:43Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019, Boston, MA, USA, 8-12 November 2019. In Hepatology, 2019, v. 70 n. Suppl. 1, p. 1127A-1128A, abstract no. 1878 | - |
dc.identifier.issn | 0270-9139 | - |
dc.identifier.uri | http://hdl.handle.net/10722/280993 | - |
dc.description | Poster Abstract - no. 1878 | - |
dc.description.abstract | Background: Diabetes mellitus is associated with adverse liver-related outcomes including liver decompensation and hepatocellular carcinoma. Its specific interaction with chronic hepatitis B (CHB) and related liver fibrosis is not wellunderstood . Methods: We prospectively recruited consecutive CHB patients with concomitant type 2 diabetes mellitus . Anthropometry, metabolic parameters, liver biochemistry and virologic profiles were measured. Detailed diabetic history (duration, treatment, glycemic control, complications) was collected. Liver fibrosis and steatosis were assessed by transient elastography (Fibroscan, Echosens), with severe fibrosis defined following the European Association of the Study of the Liver guidelines for CHB (liver stiffness [LS]>9.0 kPa with normal alanine aminotransferase (ALT) level, or >12.0 kPa with ALT one to five times above the upper limit of normal) . Results: 755 diabetic CHB patients (mean age 63 .1±9 .6 years, 65 .7% male) were recruited . 488 (64 .6%) were on nucleoside analogue treatment for a median duration of 6.6 years. The median duration of diabetes was 8.8 (IQR 4.5– 14.7) years. Median LS was 6.8 (IQR 5.2–10.3) kPa, with 218 (28.9%) having severe liver fibrosis. 94 (12.5%) and 57 (7.5%) were on sitagliptin and other dipeptidyl peptidase-4 inhibitors (DPP-4is) respectively . By multivariable analysis, after controlling for CHB treatment status, metabolic comorbidities, diabetes duration, presence of diabetic complications and time-weighted glycosylated haemoglobin levels since diabetes diagnosis, the use of sitagliptin was independently associated with severe liver fibrosis (OR 2.04, 95%CI 1.19–3.48; p=0.009). Sitagliptin use for >3 years was similarly associated (OR 2 .68, 95% CI 1 .11-6 .51; p=0 .029) . Other DPP-4is did not show such association (p=0 .405) . Additional associated factors included severe steatosis (controlled attenuation parameter ≥280 dB/m) (OR 1.97, 95%CI 1.16–3.33; p=0.012) and the presence of diabetic microvascular complications (OR 1 .60, 95%CI 1 .07-2 .39; p=0 .024) . Statins treatment was the only negative predictor of severe liver fibrosis (OR 0.52, 95%CI 0 .35–0 .77; p=0 .001) . Conclusion: Sitagliptin use in diabetic CHB patients was associated with an increased risk of severe liver fibrosis. Its potential fibrogenic effect requires longitudinal and mechanistic validation. [https://doi.org/10.1002/hep.30941] | - |
dc.language | eng | - |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ | - |
dc.relation.ispartof | Hepatology | - |
dc.relation.ispartof | The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019 | - |
dc.title | Sitagliptin Use in a Large Cohort of Chronic Hepatitis B with Concomitant Diabetes was Associated with Increased Risk of Severe Liver Fibrosis | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Lee, CHP: pchlee@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Lee, CHP=rp02043 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.hkuros | 309226 | - |
dc.identifier.volume | 70 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | 1127A | - |
dc.identifier.epage | 1128A | - |
dc.identifier.isi | WOS:000488653504151 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0270-9139 | - |